These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19801025)

  • 1. Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris.
    Cortese B; Picchi A; Micheli A; Ebert AG; Parri F; Severi S; Limbruno U
    Am J Cardiol; 2009 Oct; 104(8):1063-8. PubMed ID: 19801025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
    Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
    Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
    Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
    N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prolonged Bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study).
    Cortese B; Limbruno U; Severi S; De Matteis S; Diehl L; Pitì A
    Am J Cardiol; 2011 Nov; 108(9):1220-4. PubMed ID: 21855837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.
    Schulz S; Mehilli J; Ndrepepa G; Neumann FJ; Birkmeier KA; Kufner S; Richardt G; Berger PB; Schömig A; Kastrati A;
    Eur Heart J; 2010 Mar; 31(5):582-7. PubMed ID: 20150324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.
    Lupi A; Schaffer A; Rognoni A; Cavallino C; Bongo AS; Cortese B; Jaffe AS; Angiolillo DJ; Porto I
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):391-397. PubMed ID: 27541144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy.
    Kuchulakanti P; Wolfram R; Torguson R; Rha SW; Cheneau E; Clavijo L; Chu WW; Pinnow EE; Canos D; Satler LF; Suddath WO; Pichard AD; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2005; 6(4):154-9. PubMed ID: 16326376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
    Sheikh-Taha M; Ghosn S
    J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
    Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of prolonged bivalirudin infusions following percutaneous coronary intervention.
    Moser LR; Nemerovski CW; Good KL
    Cardiovasc Drugs Ther; 2011 Jun; 25(3):267-76. PubMed ID: 21479645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction.
    Sejersten M; Nielsen SL; Engstrøm T; Jørgensen E; Clemmensen P
    Am J Cardiol; 2009 Jun; 103(12):1635-40. PubMed ID: 19539068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of periprocedural bivalirudin infusion in patients with chronic total occlusion lesion undergoing percutaneous coronary intervention].
    Kong LD; Wang G; Han YL; Li G; Li XY; Liu ZX; Tao J; Li Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Jul; 46(7):543-548. PubMed ID: 30032545
    [No Abstract]   [Full Text] [Related]  

  • 17. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
    Gurm HS; Rajagopal V; Fathi R; Vivekanathan D; Yadav JS; Bhatt DL; Ellis SG; Lincoff AM; Topol EJ
    Am J Cardiol; 2005 Mar; 95(6):716-21. PubMed ID: 15757596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry).
    Muhlestein JB; Hackett IS; May HT; Bair TL; Le VT; Anderson JL; Whisenant B; Knowlton KU; Lappé DL
    Am J Cardiol; 2019 Jun; 123(12):1927-1934. PubMed ID: 30981419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.